The Changes of Quality of Life in Cancer Patients Treated with Chemotherapy

화학치료를 받는 암 환자 '삶의 질'의 변화에 관한 연구

  • Kim, Byung-Soo (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Choi, In-Keun (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Park, Kyeung-Hwa (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Yoon, So-Young (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Oh, Sang-Chul (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Seo, Jae-Hong (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Choi, Chul-Won (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Shin, Sang-Won (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Kim, Yeul-Hong (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center) ;
  • Kim, Jun-Suk (Division of Oncology & Hematology, Department of Internal Medicine, Korea University Medical Center)
  • 김병수 (고려대학교 의료원 종양혈액내과) ;
  • 최인근 (고려대학교 의료원 종양혈액내과) ;
  • 박경화 (고려대학교 의료원 종양혈액내과) ;
  • 윤소영 (고려대학교 의료원 종양혈액내과) ;
  • 오상철 (고려대학교 의료원 종양혈액내과) ;
  • 서재홍 (고려대학교 의료원 종양혈액내과) ;
  • 최철원 (고려대학교 의료원 종양혈액내과) ;
  • 신상원 (고려대학교 의료원 종양혈액내과) ;
  • 김열홍 (고려대학교 의료원 종양혈액내과) ;
  • 김준석 (고려대학교 의료원 종양혈액내과)
  • Published : 2001.12.01

Abstract

Purpose : It is very important to endow the cancer patients underwent chemotherapy with satisfactory quality of life (QOL). However, little is known about the factors influencing QOL during chemotherapy. Therefore, we designed this study to find out the factors influencing QOL in the cancer patients who underwent chemotherapy. Methods : Ninety-seven cancer patients were studied, prospectively. The patients' characteristics were as follows; median age(range): 48(19{\sim}83) years, male:female; 57:40, PS:0,1/2,3;55/42 patients, diagnosis(number): lymphoma (28), lung cancer (22), gastrointestinal cancer (18), sarcoma (12), breast cancer (12), gynecological cancer (5), Stage: I,II/III.IV;37/60 patients. We used EORTC QLQ-C30 questionnaires to evaluate QOL. EORTC QLQ-C30 scores were performed before the onset of chemotherapy and after the end of 3 cycles of chemotherapy. The correlation of these scores with performance status (PS), diagnosis, disease stage, response to chemotherapy, and regimen related toxicity was evaluated. Results : The responder group (CR, PR) demonstrated marked improvement of social functional and emotional scales to non-responder group (SD,PD) (P=0.024, 0.045). Non-hematologic regimen related toxicity such as mucositis, nausea and vomiting was significantly correlated with pain scale change (P=0.043). Other factors had no notable correlation with QOL changes. Conclusion : Our preliminary study results may suggest as follows. The response to chemotherapy is associated with the change of social functional and emotional scales and the severity of non-hematologic regimen related toxicity is associated with pain scale change.

Keywords